Company newsCompany release
Beam Therapeutics BEAM
Risto-cel meets primary endpoint of at least 12 months free of severe VOCs
Beam Therapeutics also said the study met all secondary endpoints and expects to submit a U.S. biologics license application as early as year-end 2026.
GetSignal
Beam Therapeutics said on November 10, 2026, that topline results from its BEACON Phase 1/2 study of risto-cel in patients with sickle cell disease and severe vaso-occlusive crises were positive. The study achieved its primary efficacy endpoint of freedom from severe vaso-occlusive crises for at least 12 consecutive months, based on independently adjudicated results, and met all primary safety endpoints at a prespecified interim analysis.
Key facts
- Trial
- BEACON Phase 1/2 study
- Drug
- Risto-cel (ristoglogene autogetemcel)
- Primary efficacy endpoint
- Freedom from severe vaso-occlusive crises for at least 12 consecutive months
- Planned U.S. BLA submission
- As early as year-end 2026
Source: The company's release on GlobeNewswire, November 10, 2026.
Written by GetSignal with AI from the company's press release. How we make news
Not investment advice.
More company news
The newest- Western Digital stockholders elect nine directors at annual meeting
WDC · Western Digital · Form 8-K · Nov 20, 2026
- Ares Capital subsidiary amends BNP Paribas funding facility
ARCC · Ares Capital · Form 8-K · Nov 20, 2026
- FACT II Acquisition extends business combination deadline to November 25, 2027
FACT · FACT II Acquisition · Form 8-K · Nov 20, 2026
- SELLAS Life Sciences Group closes public offering for $172.5 million gross
SLS · SELLAS Life Sciences Group · Company release · Nov 20, 2026
